Treatment
Dupilumab clinical trials
We’re tracking 52 recruiting studies that include Dupilumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT06477653RecruitingPhase 2
Dupilumab for hypereosinophilic syndrome with ongoing symptoms
This trial tests if dupilumab, added to your current treatment, can help with remaining symptoms of hypereosinophilic syndrome (HES) like asthma, eczema, nasal polyps, or eosinophilic esophagitis. You may qualify if you're already on a biologic therapy that lowers eosinophils but still have bothersome symptoms.
Bethesda, MarylandAges 18–99 - NCT06293053RecruitingPhase 3
Dupilumab for children with prurigo nodularis
This study tests whether the medication dupilumab can safely reduce itching and skin bumps in children aged 6 months to under 18 years who have prurigo nodularis, a skin condition that causes intense itching and nodules. Participation involves taking the study drug and tracking itch daily.
Palo Alto, CaliforniaAges 6 months–17 years - NCT06191315Enrolling by invitationPhase 3
Dupilumab for asthma and wheezing in young children
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
Phoenix, ArizonaAges 2–5 - NCT06192563Recruiting
Dupilumab for severe eczema with limited skin rash
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
BolognaAges 6 months–17 years - NCT06004986RecruitingPhase 4
Lowering Dupilumab Dose in Controlled Eczema
This study looks at whether people with well-controlled eczema can safely lower their dose of dupilumab (an injected medication). It aims to see if a reduced dose still keeps eczema under control.
Amsterdam, North HollandAges 18 years+ - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT05268107RecruitingPhase 4
Study dupilumab skin effects in different ethnic groups
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Ann Arbor, MichiganAges 18 years+ - NCT05858619RecruitingPhase 4
Study of skin response to dupilumab in eczema
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
San Francisco, CaliforniaAges 18 years+ - NCT05866562RecruitingPhase 2
Dupilumab for hair regrowth in kids with alopecia areata
This trial studies dupilumab (an injection medicine) to help grow hair in children and teens with alopecia areata, an autoimmune hair-loss condition. It aims to see whether the treatment improves hair regrowth compared with usual care over the study period.
Irvine, CaliforniaAges 6–17 - NCT05649098RecruitingEarly Phase 1
Testing dupilumab for itchy inherited genetic skin disorders
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
Chicago, IllinoisAges 6 months+ - NCT05551793RecruitingPhase 2
Dupilumab for patchy hair loss with scalp inflammation
This Phase 2 trial tests dupilumab (an injection medicine) to regrow hair in people with alopecia areata, a condition where the immune system attacks hair follicles. It may help by reducing the immune-related inflammation linked to hair loss.
Irvine, CaliforniaAges 18 years+ - NCT05042258RecruitingPhase 4
Dupilumab to improve sleep and itch in children with eczema
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
Chicago, IllinoisAges 6–17 - NCT04743791RecruitingPhase 4
Dupilumab study for clearing mucus in moderate to severe asthma
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05790330Recruiting
Study brain–skin links in teenagers with eczema
This study looks at how eczema may be connected to the brain and sleep, using questionnaires and MRI scans. It may help researchers understand what drives symptoms and how treatments could be improved.
LondonAges 12–18 - NCT06385236RecruitingPhase 4
Asthma genetics study to find better treatments
This study looks at how your genes affect your asthma medications. It tests if knowing your DNA can help predict which treatment works best for you and why.
Scottsdale, ArizonaAges 18–75 - NCT06234761Recruiting
Study on immune responses in nasal polyps
This trial looks at how the immune system reacts in people with nasal polyps. It may help doctors better understand and treat this condition.
GhentAges 18 years+ - NCT06683261Recruiting
Real-world study of biologics for nasal polyps
This study follows people with chronic rhinosinusitis and nasal polyps who are starting a biologic medication (omalizumab, mepolizumab, or dupilumab) to see how well it works in real life.
AalstAges 18 years+ - NCT07399067RecruitingPhase 2
Testing IBI3002 for moderate to severe eczema
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Beijing, Beijing MunicipalityAges 18–75 - NCT07380711Recruiting
How dupilumab works for COPD in real life
This study looks at how well dupilumab works for people with uncontrolled COPD who have high levels of a certain white blood cell (eosinophils). It collects information from routine doctor visits to see how patients feel and if the treatment is safe.
Aix-en-ProvenceAges 18 years+ - NCT07358234Enrolling by invitationEarly Phase 1
Comparing two EoE treatments on esophagus widening
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
Scottsdale, ArizonaAges 18 years+ - NCT07330934RecruitingPhase 2
Study of IBI356 for moderate to severe eczema
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04380038RecruitingPhase 4
Viral infection study in well-controlled asthma adults
This study looks at how a viral infection affects people with well-controlled asthma. It tests whether specific asthma-related immune signals can predict who reacts more to a virus, which may help guide future asthma care.
Charlottesville, VirginiaAges 18–40 - NCT07025200Recruiting
Severe asthma study using bronchoscopy to check treatment
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
Vienna, State of ViennaAges 18 years+
Common questions
- Are there clinical trials studying Dupilumab?
- Yes. Clin2 currently lists 52 recruiting studies that include Dupilumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dupilumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dupilumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dupilumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.